Laboratory of Cellular Physiology and Immunology and The Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10065, USA.
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9. doi: 10.1073/pnas.1019547108. Epub 2011 Jan 24.
Improved protein-based vaccines should facilitate the goal of effective vaccines against HIV and other pathogens. With respect to T cells, the efficiency of immunization, or "immunogenicity," is improved by targeting vaccine proteins to maturing dendritic cells (DCs) within mAbs to DC receptors. Here, we compared the capacity of Langerin/CD207, DEC205/CD205, and Clec9A receptors, each expressed on the CD8(+) DC subset in mice, to bring about immunization of microbial-specific T cells from the polyclonal repertoire, using HIV gag-p24 protein as an antigen. α-Langerin mAb targeted splenic CD8(+) DCs selectively in vivo, whereas α-DEC205 and α-Clec9A mAbs targeted additional cell types. When the mAb heavy chains were engineered to express gag-p24, the α-Langerin, α-DEC205, and α-Clec9A fusion mAbs given along with a maturation stimulus induced comparable levels of gag-specific T helper 1 (Th1) and CD8(+) T cells in BALB/c × C57BL/6 F1 mice. These immune T cells were more numerous than targeting the CD8(-) DC subset with α-DCIR2-gag-p24. In an in vivo assay in which gag-primed T cells were used to report the early stages of T-cell responses, α-Langerin, α-DEC205, and α-Clec9A also mediated cross-presentation to primed CD8(+) T cells if, in parallel to antigen uptake, the DCs were stimulated with α-CD40. α-Langerin, α-DEC205, and α-Clec9A targeting greatly enhanced T-cell immunization relative to nonbinding control mAb or nontargeted HIV gag-p24 protein. Therefore, when the appropriate subset of DCs is targeted with a vaccine protein, several different receptors expressed by that subset are able to initiate combined Th1 and CD8(+) immunity.
改良的基于蛋白质的疫苗应该有助于实现针对 HIV 和其他病原体的有效疫苗这一目标。就 T 细胞而言,通过将疫苗蛋白靶向 mAb 中的成熟树突状细胞 (DC) 内的 DC 受体,可以提高免疫原性或“免疫性”。在这里,我们比较了朗格汉斯蛋白/CD207、DEC205/CD205 和 Clec9A 受体的能力,这些受体都在小鼠的 CD8(+) DC 亚群上表达,以利用 HIV gag-p24 蛋白作为抗原,从多克隆 repertoire 中引发微生物特异性 T 细胞的免疫。α-Langerin mAb 体内选择性靶向脾 CD8(+) DC,而 α-DEC205 和 α-Clec9A mAb 则靶向其他细胞类型。当 mAb 重链被设计表达 gag-p24 时,α-Langerin、α-DEC205 和 α-Clec9A 融合 mAb 与成熟刺激物一起给予,在 BALB/c×C57BL/6 F1 小鼠中诱导相当水平的 gag 特异性辅助性 T 细胞 1 (Th1) 和 CD8(+) T 细胞。这些免疫 T 细胞比靶向用 α-DCIR2-gag-p24 靶向的 CD8(-) DC 亚群更多。在体内试验中,使用 gag 引发的 T 细胞报告 T 细胞反应的早期阶段,如果在摄取抗原的同时,DC 被 α-CD40 刺激,α-Langerin、α-DEC205 和 α-Clec9A 也介导交叉呈递给引发的 CD8(+) T 细胞。与非结合对照 mAb 或非靶向 HIV gag-p24 蛋白相比,α-Langerin、α-DEC205 和 α-Clec9A 靶向极大地增强了 T 细胞免疫。因此,当用疫苗蛋白靶向适当的 DC 亚群时,该亚群表达的几个不同受体能够引发联合 Th1 和 CD8(+) 免疫。
Proc Natl Acad Sci U S A. 2009-2-3
Vaccines (Basel). 2025-3-25
Cancer Immunol Immunother. 2024-1-17
Exp Biol Med (Maywood). 2023-10
Immunol Rev. 2010-3
Clin Vaccine Immunol. 2009-12
Eur J Immunol. 2009-4
Proc Natl Acad Sci U S A. 2009-2-3